Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Revenue of Trevena, Inc. (TRVN)
Revenue in 2023 (TTM): $3.13 M
According to Trevena, Inc.'s latest financial reports the company's current revenue (TTM) is $3.13 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Trevena, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $3.13 M | $1.46 M | $-34,954,000 | $-39,971,000 | $-40,289,000 |
| 2022 | $-418,000 | $-3,436,000 | $-56,375,000 | $-53,670,000 | $-53,667,295 |
| 2021 | $567 K | $-387,000 | $-51,925,000 | $-51,588,000 | $-51,160,000 |
| 2020 | $3.07 M | $2.89 M | $-29,485,000 | $-29,069,000 | $-29,369,000 |
| 2019 | $31 K | $-77,000 | $-23,238,000 | $-24,871,000 | $-28,056,000 |
| 2018 | $5.73 M | $5.73 M | $-27,644,000 | $-30,039,000 | $-30,784,000 |
| 2017 | $ | $-490,000 | $-66,830,000 | $-71,865,000 | $-71,865,000 |
| 2016 | $3.75 M | $3.75 M | $-102,283,000 | $-102,994,000 | $-102,994,000 |
| 2015 | $6.25 M | $-37,824,000 | $-50,621,167 | $-50,528,240 | $-50,528,240 |
| 2014 | $ | $-40,547,000 | $-49,509,143 | $-49,700,875 | $-49,700,875 |
| 2013 | $134.98 K | $-18,627,239 | $-22,636,378 | $-23,251,435 | $-23,251,435 |
| 2012 | $807.6 K | $-12,487,322 | $-14,698,972 | $-15,635,658 | $-15,635,658 |
| 2011 | $2.42 M | $2.42 M | $-14,945,092 | $-15,810,004 | $-15,810,004 |